NeoGenomics (STU:NG9) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NG9 NeoGenomics Inc STU:NG9
77 GF Score
Price €12.75
GF Value €14.55
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NeoGenomics Valuation Rank Related Terms

STU:NG9
77GF Score
NeoGenomics Inc STU:NG9
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NeoGenomics (STU:NG9) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of €12.75 is trading 12.4% below its estimated GF Value™ of €14.55. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for STU:NG9:

  • Valuation Rank:
  • GF Value™: €14.55 vs. price of €12.75 (12.4% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the STU:NG9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
77GF Score

Get the complete analysis for STU:NG9

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.75
Price
€14.55
GF Value